Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRNP-targeted siRNA
- Development stage
- Preclinical
- Lead developer
- Alabama State University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Rectal, Intrathecal
01
Overview
PRNP-targeted siRNA is an experimental small interfering RNA (siRNA) designed to silence the expression of the *PRNP* gene, which encodes the cellular prion protein (PrPc). In the context of triple-negative breast cancer (TNBC), PrPc has been identified as a promoter of tumor aggressiveness, facilitating migration, invasion, and proliferation. By transiently silencing *PRNP*, this siRNA attenuates the canonical WNT/β-catenin signaling pathway, leading to reduced β-catenin levels and a shift in epithelial-mesenchymal transition (EMT) markers, such as increased E-cadherin and decreased N-cadherin expression. This molecular intervention results in growth arrest in the G0 phase and reduced metabolic activity in cancer cells, suggesting that targeting PrPc may offer a promising therapeutic strategy to limit the aggressiveness of TNBC.
- Other names
- PRNP siRNAcellular prion protein-targeted siRNAPrP-targeted siRNA
02
Targets
PRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on PRNP-targeted siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRNP-targeted siRNA.